430 related articles for article (PubMed ID: 27000249)
1. Alemtuzumab improves neurological functional systems in treatment-naive relapsing-remitting multiple sclerosis patients.
Fox EJ; Wynn D; Coles AJ; Palmer J; Margolin DH;
J Neurol Sci; 2016 Apr; 363():188-94. PubMed ID: 27000249
[TBL] [Abstract][Full Text] [Related]
2. Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.
Giovannoni G; Cohen JA; Coles AJ; Hartung HP; Havrdova E; Selmaj KW; Margolin DH; Lake SL; Kaup SM; Panzara MA; Compston DA;
Neurology; 2016 Nov; 87(19):1985-1992. PubMed ID: 27733571
[TBL] [Abstract][Full Text] [Related]
3. Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.
Coles AJ; Fox E; Vladic A; Gazda SK; Brinar V; Selmaj KW; Bass AD; Wynn DR; Margolin DH; Lake SL; Moran S; Palmer J; Smith MS; Compston DA
Lancet Neurol; 2011 Apr; 10(4):338-48. PubMed ID: 21397567
[TBL] [Abstract][Full Text] [Related]
4. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
Cohen JA; Coles AJ; Arnold DL; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Fisher E; Brinar VV; Giovannoni G; Stojanovic M; Ertik BI; Lake SL; Margolin DH; Panzara MA; Compston DA;
Lancet; 2012 Nov; 380(9856):1819-28. PubMed ID: 23122652
[TBL] [Abstract][Full Text] [Related]
5. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
Coles AJ; Twyman CL; Arnold DL; Cohen JA; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Miller T; Fisher E; Sandbrink R; Lake SL; Margolin DH; Oyuela P; Panzara MA; Compston DA;
Lancet; 2012 Nov; 380(9856):1829-39. PubMed ID: 23122650
[TBL] [Abstract][Full Text] [Related]
6. Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial.
Coles AJ; Fox E; Vladic A; Gazda SK; Brinar V; Selmaj KW; Skoromets A; Stolyarov I; Bass A; Sullivan H; Margolin DH; Lake SL; Moran S; Palmer J; Smith MS; Compston DA
Neurology; 2012 Apr; 78(14):1069-78. PubMed ID: 22442431
[TBL] [Abstract][Full Text] [Related]
7. Relationship between sustained disability progression and functional system scores in relapsing-remitting multiple sclerosis: analysis of placebo data from four randomized clinical trials.
Scott T; Wang P; You X; Mann M; Sperling B
Neuroepidemiology; 2015; 44(1):16-23. PubMed ID: 25634764
[TBL] [Abstract][Full Text] [Related]
8. Alemtuzumab improves contrast sensitivity in patients with relapsing-remitting multiple sclerosis.
Graves J; Galetta SL; Palmer J; Margolin DH; Rizzo M; Bilbruck J; Balcer LJ
Mult Scler; 2013 Sep; 19(10):1302-9. PubMed ID: 23459567
[TBL] [Abstract][Full Text] [Related]
9. Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis.
Daniels GH; Vladic A; Brinar V; Zavalishin I; Valente W; Oyuela P; Palmer J; Margolin DH; Hollenstein J
J Clin Endocrinol Metab; 2014 Jan; 99(1):80-9. PubMed ID: 24170099
[TBL] [Abstract][Full Text] [Related]
10. Alemtuzumab: evidence for its potential in relapsing-remitting multiple sclerosis.
Brown JW; Coles AJ
Drug Des Devel Ther; 2013; 7():131-8. PubMed ID: 23494602
[TBL] [Abstract][Full Text] [Related]
11. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.
; Coles AJ; Compston DA; Selmaj KW; Lake SL; Moran S; Margolin DH; Norris K; Tandon PK
N Engl J Med; 2008 Oct; 359(17):1786-801. PubMed ID: 18946064
[TBL] [Abstract][Full Text] [Related]
12. Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis.
Arroyo González R; Kita M; Crayton H; Havrdova E; Margolin DH; Lake SL; Giovannoni G;
Mult Scler; 2017 Sep; 23(10):1367-1376. PubMed ID: 27885061
[TBL] [Abstract][Full Text] [Related]
13. Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.
Hersh CM; Cohen JA
Immunotherapy; 2014; 6(3):249-59. PubMed ID: 24762071
[TBL] [Abstract][Full Text] [Related]
14. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study.
Ziemssen T; Bass AD; Berkovich R; Comi G; Eichau S; Hobart J; Hunter SF; LaGanke C; Limmroth V; Pelletier D; Pozzilli C; Schippling S; Sousa L; Traboulsee A; Uitdehaag BMJ; Van Wijmeersch B; Choudhry Z; Daizadeh N; Singer BA;
CNS Drugs; 2020 Sep; 34(9):973-988. PubMed ID: 32710396
[TBL] [Abstract][Full Text] [Related]
16. Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of the CARE-MS Studies.
Hunter SF; Aburashed RA; Alroughani R; Chan A; Dive D; Eichau S; Kantor D; Kim HJ; Lycke J; Macdonell RAL; Pozzilli C; Scott T; Sharrack B; Wiendl H; Chung L; Daizadeh N; Baker DP; Vermersch P;
Neurol Ther; 2021 Dec; 10(2):803-818. PubMed ID: 34165694
[TBL] [Abstract][Full Text] [Related]
17. Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis.
Burt RK; Balabanov R; Han X; Sharrack B; Morgan A; Quigley K; Yaung K; Helenowski IB; Jovanovic B; Spahovic D; Arnautovic I; Lee DC; Benefield BC; Futterer S; Oliveira MC; Burman J
JAMA; 2015 Jan; 313(3):275-84. PubMed ID: 25602998
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies.
Van Wijmeersch B; Singer BA; Boster A; Broadley S; Fernández Ó; Freedman MS; Izquierdo G; Lycke J; Pozzilli C; Sharrack B; Steingo B; Wiendl H; Wray S; Ziemssen T; Chung L; Margolin DH; Thangavelu K; Vermersch P
Mult Scler; 2020 Nov; 26(13):1719-1728. PubMed ID: 31675266
[TBL] [Abstract][Full Text] [Related]
19. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
Ravnborg M; Sørensen PS; Andersson M; Celius EG; Jongen PJ; Elovaara I; Bartholomé E; Constantinescu CS; Beer K; Garde E; Sperling B
Lancet Neurol; 2010 Jul; 9(7):672-80. PubMed ID: 20542736
[TBL] [Abstract][Full Text] [Related]
20. Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223.
Steingo B; Al Malik Y; Bass AD; Berkovich R; Carraro M; Fernández Ó; Ionete C; Massacesi L; Meuth SG; Mitsikostas DD; Pardo G; Simm RF; Traboulsee A; Choudhry Z; Daizadeh N; Compston DAS;
J Neurol; 2020 Nov; 267(11):3343-3353. PubMed ID: 32583052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]